Abu-Hilal Mohannad, Cowger Jeff, Bawazir Mohammed, Sajic Dusan, Savinova Iryna, Yap Belinda, El-Sayegh Rami, Bolatova Talshyn, Chan Pak, Cy Ajith
Division of Dermatology, McMaster University, Hamilton, ON, Canada.
Skin Therapy Centre, Advanced Medical Group, London, ON, Canada.
J Cutan Med Surg. 2025 Mar-Apr;29(2):137-142. doi: 10.1177/12034754241302827. Epub 2024 Dec 14.
Tildrakizumab is an interleukin-23 inhibitor approved in Canada in 2021 for the treatment of adults with moderate-to-severe plaque psoriasis.
To evaluate real-world effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Canada.
A multicenter, retrospective study was conducted in Canada in adults with moderate-to-severe plaque psoriasis for ≥1 year treated with tildrakizumab for ≥12 weeks. Effectiveness was evaluated from proportions of patients achieving ≥75%/≥90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 75/90/100 response) and Physician Global Assessment (PGA) 0 or 1 at weeks 16 (±4), 24 (±8), and 48 (±12). Subgroup analyses were performed based on prior biologic use and special site involvement.
The study included 75 patients (mean age, 50.5 years; 52.0% female; 82.7% bio-naïve; 73.3% with special site involvement). Absolute mean (standard deviation) PASI score improved from 16.1 (6.7) at baseline to 1.3 (1.7) at the week 48 (91.7% improvement), 95.7%/69.6%/34.8% of patients achieved PASI 75/90/100 response, and 93.0% achieved PGA 0/1 at the week 48. In subgroup analyses, 94.7%/71.1%/34.2% of bio-naïve patients, 100.0%/62.5%/37.5% of bio-experienced patients, 100.0%/71.4%/28.6% of patients with special site involvement, and 81.8%/63.6%/54.6% of patients without special site involvement achieved PASI 75/90/100 response, and 87.5%, 94.3%, 97.0%, and 80.0% of patients, respectively, achieved PGA 0/1 at the week 48. None of the differences among subgroups were statistically significant; however, patient numbers were too small to support robust conclusions.
Tildrakizumab is effective for the treatment of moderate-to-severe plaque psoriasis in adults in a real-world setting in Canada.
替拉珠单抗是一种白细胞介素-23抑制剂，于2021年在加拿大获批用于治疗中度至重度斑块状银屑病成人患者。
评估替拉珠单抗在加拿大治疗中度至重度斑块状银屑病的真实疗效。
在加拿大对中度至重度斑块状银屑病病程≥1年且接受替拉珠单抗治疗≥12周的成人患者进行了一项多中心回顾性研究。在第16周（±4周）、24周（±8周）和48周（±12周），根据银屑病面积和严重程度指数（PASI 75/90/100缓解）以及医师整体评估（PGA）为0或1的患者比例评估疗效。基于既往生物制剂使用情况和特殊部位受累情况进行亚组分析。
该研究纳入了75例患者（平均年龄50.5岁；52.0%为女性；82.7%为初治患者；73.3%有特殊部位受累）。PASI绝对平均（标准差）评分从基线时的16.1（6.7）改善至第48周时的1.3（1.7）（改善91.7%），95.7%/69.6%/34.8%的患者达到PASI 75/90/100缓解，93.0%的患者在第48周时达到PGA 0/1。在亚组分析中，初治患者中94.7%/71.1%/34.2%、经治患者中100.0%/62.5%/37.5%、有特殊部位受累患者中100.0%/71.4%/28.6%以及无特殊部位受累患者中81.8%/63.6%/54.6%达到PASI 75/90/100缓解，第48周时分别有87.5%、94.3%、97.0%和80.0%的患者达到PGA 0/1。亚组间差异均无统计学意义；然而，患者数量过少，无法支持得出有力结论。
在加拿大的真实临床环境中，替拉珠单抗对治疗成人中度至重度斑块状银屑病有效。
